Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD/MAD of XTL6001 in Healthy and Obese Subjects
NCT07205432Phase 1Recruiting
- Sponsor
- Shanghai Xitaili Biomedical Technology Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing XTL6001 with Placebo (2 arms). Primary endpoint: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 57. Started Jun 2025; status: recruiting.
02
Drugs
XTL6001
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07205432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07205432.